BiotechTube
Home/MapLight Therapeutics/Megan D. Schmidt, J.D.
MD

Megan D. Schmidt, J.D.

Chief Business Officer and General Counsel

MapLight Therapeutics

Therapeutic Areas

NeuropsychiatryNeurologyAutism Spectrum DisorderSchizophreniaDepressionAlzheimer's Disease

MapLight Therapeutics Pipeline

DrugIndicationPhase
ML-007Social impairment in Autism Spectrum DisorderPhase 2
ML-104Treatment-resistant DepressionPreclinical
ML-225Cognitive impairment in Alzheimer's DiseasePreclinical
Undisclosed ProgramAnxiety DisordersDiscovery

Leadership Team at MapLight Therapeutics

CG
Christopher G. Verni, Ph.D.
Chief Executive Officer
DL
David L. Gray, Ph.D.
Chief Scientific Officer
MA
M. Amin Khan, Ph.D.
Chief Development Officer
SB
Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
JA
James A. Johnson, CPA
Chief Financial Officer
RA
Richard A. Scheller, Ph.D.
Chairman of the Board of Directors
KB
Katrine Bosley
Director
BE
Bryan E. Roberts, Ph.D.
Director
BS
Beth Seidenberg, M.D.
Director
KA
Katherine A. High, M.D.
Director
View full MapLight Therapeutics profile